Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial
2024 · Nature Medicine · 87 citations
https://doi.org/10.1038/s41591-024-03050-2
F
François Vergez
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
476
Papers
4.0K
Citations
28
h-index
62
i10-index
François Vergez is an academic researcher from Centre National de la Recherche Scientifique. The author has contributed to research in topics: Cancer, Lipids, and Metabolism & Ferroptosis and cancer prognosis & Acute Myeloid Leukemia Research. The author has an h-index of 28, co-authored 405 publications.
ORCID: 0000-0002-0063-4404Papers by this author
worksA robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
2015 · Blood Cancer Journal · 84 citations
https://doi.org/10.1038/bcj.2015.19
Adrenomedullin-CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells
2021 · Nature Communications · 62 citations
https://doi.org/10.1038/s41467-020-20717-9
Somatic genetic alterations predict hematological progression in GATA2 deficiency
2023 · Haematologica · 37 citations
https://doi.org/10.3324/haematol.2022.282250
In vivo metabolomic study uncovers distinct metabolic phenotypes of host tissues and predicts oxidative state of acute myeloid leukemia
2021 · Research Square · 0 citations
https://doi.org/10.21203/rs.3.rs-719532/v1
Table S3 from CD36 drives metastasis and relapse in acute myeloid leukemia
2024 · 0 citations
https://doi.org/10.1158/0008-5472.27028276
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat